44
Participants
Start Date
July 31, 2017
Primary Completion Date
November 30, 2023
Study Completion Date
November 30, 2023
Tumor biopsy
Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
Peripheral blood draw
-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
Lymphotrack TCR clonality assay
-Assay with high sensitivity that can be performed with peripheral blood
Memorial Sloan Kettering Cancer Center, New York
Washington University School of Medicine, St Louis
Dana Farber Cancer Institute, Boston
Invivoscribe, Inc.
INDUSTRY
National Cancer Institute (NCI)
NIH
T-Cell Leukemia Lymphoma Foundation
UNKNOWN
Washington University School of Medicine
OTHER